Your session is about to expire
← Back to Search
EZH2 Inhibitor
Tazemetostat for Prostate Cancer
Phase < 1
Waitlist Available
Led By Edwin Posadas, MD FACP
Research Sponsored by Edwin Posadas, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the start of study treatment until documented progression, or death due to any cause. assessed up to 5 years.
Awards & highlights
Study Summary
This trial is testing a new way to treat prostate cancer by inhibiting EZH2. Blood and tissue will be collected before and after surgery to see if this treatment makes the tumor more sensitive to the patient's immune system.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from the start of study treatment until documented progression, or death due to any cause. assessed up to 5 years.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the start of study treatment until documented progression, or death due to any cause. assessed up to 5 years.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of adverse events, serious adverse events, and treatment-related adverse events.
Operative Surgical Procedures
Proportion of patients with Grade 3 or above treatment related adverse events
+1 moreSecondary outcome measures
Clinical Progression Free Survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: TazemetostatExperimental Treatment1 Intervention
Tazemetostat 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
Find a Location
Who is running the clinical trial?
Edwin Posadas, MDLead Sponsor
2 Previous Clinical Trials
117 Total Patients Enrolled
1 Trials studying Prostate Cancer
17 Patients Enrolled for Prostate Cancer
Epizyme, Inc.Industry Sponsor
33 Previous Clinical Trials
2,854 Total Patients Enrolled
Edwin Posadas, MD FACPPrincipal InvestigatorCedars-Sinai Medical Center
3 Previous Clinical Trials
128 Total Patients Enrolled
2 Trials studying Prostate Cancer
28 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have another illness or cancer that needs treatment, aside from prostate cancer.You have already taken tazemetostat before.
Research Study Groups:
This trial has the following groups:- Group 1: Tazemetostat
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there opportunities to participate in this research study at present?
"As displayed on clinicaltrials.gov, this trial is not currently enrolling patients; however, it was initially posted in November 1st 2022 and the last update to that page occurred September 30th of the same year. Fortunately, there are over 1300 other studies actively recruiting at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger